Kastner A, Herrero M T, Hirsch E C, Guillen J, Luquin M R, Javoy-Agid F, Obeso J A, Agid Y
INSERM U289, Hôpital de la Salpêtrière, Paris, France.
Ann Neurol. 1994 Aug;36(2):206-14. doi: 10.1002/ana.410360213.
Parkinson's disease is characterized by the degeneration of melanized dopaminergic neurons of the substantia nigra. The functional capacity of the surviving dopaminergic neurons is affected, as suggested by the subnormal levels of tyrosine hydroxylase messenger RNA and protein found in the remaining cells. The reduced expression of tyrosine hydroxylase may be due to either the evolving neurodegenerative process or its downregulation, possibly secondary to chronic levodopa treatment. The cellular content of tyrosine hydroxylase was determined in the mesencephalon from 16 Macaca fascicularis monkeys, using a semiquantitative immunocytochemical method. Thirteen monkeys were rendered parkinsonian by weekly intravenous injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) for 2 (subacute treatment) or 20 (chronic treatment) weeks. Three of the monkeys received levodopa and 3 others received GM1 ganglioside. The loss of dopaminergic neurons in the mesencephalon of the MPTP-intoxicated monkeys was severe in the substantia nigra, intermediate in cell groups A8 and A10, and almost undetectable in the central gray substance. After both subacute and chronic treatment, the cellular content of tyrosine hydroxylase was reduced by 40% in the surviving neurons of the lesioned substantia nigra, but by less in the other mesencephalic dopaminergic regions. Neuronal survival and tyrosine hydroxylase content in monkeys that had received levodopa were not significantly different. The cellular content of tyrosine hydroxylase was increased in the substantia nigra of the monkeys that received GM1 ganglioside injections. The results show that the decreased expression of tyrosine hydroxylase found in nigral dopaminergic neurons after partial degeneration of the mesostriatal dopaminergic system is not influenced by levodopa treatment and is partially reversed by GM1 ganglioside administration.
帕金森病的特征是黑质中产生黑色素的多巴胺能神经元变性。存活的多巴胺能神经元的功能能力受到影响,这可从其余细胞中酪氨酸羟化酶信使核糖核酸和蛋白质水平低于正常得到提示。酪氨酸羟化酶表达降低可能是由于不断发展的神经退行性过程或其下调,可能继发于长期左旋多巴治疗。使用半定量免疫细胞化学方法,测定了16只食蟹猴中脑内酪氨酸羟化酶的细胞含量。13只猴子通过每周静脉注射1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)持续2周(亚急性治疗)或20周(慢性治疗)而患帕金森病。其中3只猴子接受左旋多巴治疗,另外3只接受GM1神经节苷脂治疗。MPTP中毒猴子中脑内多巴胺能神经元的丧失在黑质中很严重,在A8和A10细胞群中程度中等,在中央灰质中几乎检测不到。在亚急性和慢性治疗后,受损黑质中存活神经元的酪氨酸羟化酶细胞含量减少了40%,但在其他中脑多巴胺能区域减少较少。接受左旋多巴治疗的猴子的神经元存活率和酪氨酸羟化酶含量没有显著差异。接受GM1神经节苷脂注射的猴子黑质中酪氨酸羟化酶的细胞含量增加。结果表明,中脑纹状体多巴胺能系统部分变性后黑质多巴胺能神经元中发现的酪氨酸羟化酶表达降低不受左旋多巴治疗的影响,而GM1神经节苷脂给药可部分逆转这种降低。